Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0) (TAILOR-TAVR)
Transcatheter Aortic Valve Replacement For Patients With Bicuspid Aortic Stenosis (Type 0) Using Down Sizing Strategy Compared With Standard Sizing Strategy (HANGZHOU Solution): A Prospective, Multicenter, Randomized Controlled Trial
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
This NA trial investigates Aortic Stenosis With Bicuspid Valve and is currently actively recruiting participants. Second Affiliated Hospital, School of Medicine, Zhejiang University leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Nov 2025 — Present [monthly]
Recruiting NA
-
Sep 2025 — Nov 2025 [monthly]
Recruiting NA
-
Sep 2024 — Sep 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
May 2024 — Jul 2024 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
May 2023 — May 2024 [monthly]
Recruiting NA
-
Sep 2022 — May 2023 [monthly]
Recruiting NA
First recorded
Jun 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Second Affiliated Hospital, School of Medicine, Zhejiang University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Changsha, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Lanzhou, China , Nanchang, China , Ningbo, China , Qingdao, China , Xi'an, China , Xiamen, China and 3 more locations